Atlas One · Host Biology · Scale 03 — Molecular

ALK

Receptor tyrosine kinase; EML4-ALK fusions in ~3-5% of NSCLC drive constitutive ALK signaling → RAS-MAPK and PI3K-AKT; NPM-ALK defines ALK+ anaplastic large cell lymphoma; crizotinib, alectinib, brigatinib, and lorlatinib are ALK inhibitors with improving CNS penetration.

Also known as: ALK, anaplastic lymphoma kinase, EML4-ALK, NPM-ALK, ALK fusion, ALK rearrangement, ALK+ NSCLC, CD246

Scale 03 — MolecularScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
alk

ALK

Receptor tyrosine kinase; EML4-ALK fusions in ~3-5% of NSCLC drive constitutive ALK signaling → RAS-MAPK and PI3K-AKT; NPM-ALK defines ALK+ anaplastic large cell lymphoma; crizotinib, alectinib, brigatinib, and lorlatinib are ALK inhibitors with improving CNS penetration.

Entry Metadata

FieldValue
IDalk
NameALK
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale03-molecular

Cross-Atlas Connections

connects-toKras connects-toStat3 connects-toMtor connects-toEgfr connects-toLung connects-toBrain connects-toPik3Ca

Sources